Detailed Information on Publication Record
2022
Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
BACCI, Sabrina and Nathalie NICOLAYBasic information
Original name
Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update
Authors
BACCI, Sabrina and Nathalie NICOLAY
Edition
2022
Publisher
FNUSA, ECDC
Other information
Language
English
Type of outcome
Projekty výzkumu a vývoje
Field of Study
30230 Other clinical medicine subjects
Country of publisher
Sweden
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14110/22:00127692
Organization unit
Faculty of Medicine
Keywords (in Czech)
Technical Report; COVID-19; SARI
Keywords in English
Technical Report; COVID-19; SARI
Tags
International impact
Změněno: 5/4/2023 13:32, Mgr. Tereza Miškechová
Abstract
V originále
This current report builds on previous analyses [3,4,5] and extends the age groups included. An overview of outcomes, study period and age groups included in the analysis are presented in Table 1 Previous ECDC publications on COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, are available [3,4]. This third update contains vaccine effectiveness results among individuals aged 20 years and older for the Omicron period) for the first time as well as estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria).
Links
| 90128, large research infrastructures |
|